Introduction
Infection with Kaposi sarcoma-associated herpesvirus (KSHV) drives viral pathogenesis. The clinical and molecular phenotypes of these infection events are diverse and depend on the cellular environment (B cell lineage or endothelial cell lineage) as well as host cell mutations that are acquired during progressive transformation steps. KSHV pathogenesis also depends on cell extrinsic events such as co-infection with human immunodeficiency virus (HIV), degree and status of the systemic host immune response, and other host factors, which modulate the cellular environment. Currently, there is no molecular evidence that KSHV pathogenesis differs among distinct KSHV strains or clades, though SNPs in both miRNA and gene coding regions have been identified and associated with altered gene expression [1, 2] .
During much of its life cycle, the KSHV virus is present in a latent form. Here, only a very limited set of viral genes is expressed. They ensure maintenance and faithful segregation of the viral genome during host cell division and they ensure continued cell survival (reviewed in [3] ). KSHV is able to increase the life span of infected cells and primary infection induces some features, for example, activation of pro-survival signaling pathways, that are commonly seen in transformed cells [4] [5] [6] . Individual viral genes and microRNAs augment proliferation in multiple experimental systems and also modulate autophagy and oncogene-induced senescence [3,7 ,8 ,9] . To ensure continued cell survival, KSHV infection also modulates cellular immunity. Recent evidence also indicates that KSHV modulates various metabolic pathways in B cells and endothelial cells to its advantage [10 ,11 ,12] .
KSHV in endothelial cells
KSHV infects endothelial lineage cells. Clinically, KSHV infected endothelial cells constitute the bulk of Kaposi sarcoma (KS) lesions ( Figure 1 ). KS lesions are composed of elongated, spindle-like, endothelial cells. All endothelial cells within a KS tumor are infected with the virus and express the KSHV latent genes (Figure 2 ), including all viral miRNAs [13, 14] . Clinically, there is little evidence for long-term KSHV infected endothelial cells outside of KS lesions, or before KS disease manifestation. In infected endothelial lineage culture systems, KSHV is rapidly lost unless the latently infected cells undergo additional transforming events [5,6,15 ,16,17] , or the virus is selected for [18] . This suggests that infection of endothelial lineage cells with KSHV places severe selection on the host cell, leading either to viral replication, viral clearance, or persistence in a transformed cell.
The many manifestations of Kaposi sarcoma
KS manifests itself in multiple forms: (i) classic KS, which is a rare disease of the elderly, (ii) endemic KS, which is a frequent disease of children in sub-Saharan Africa and was documented before the introduction of HIV, (iii) AIDS-associated KS, which marks the terminal stages of HIV infection, and (iv) iatrogenic KS, which develops in solid organ transplant recipients (reviewed in [3] ). Endemic, HIV-negative KS is seen both in children and in adults with elevated incidence. In the absence of reliable pathology and a reliable clinical reporting structure, it is unclear whether the KS in these two age groups represent different diseases, whether there is a genetic predisposition that is associated with pediatric KS, or whether there exists age and environment specific factors. KS incidence is also elevated in isolated parts of China [19] . AIDS-associated KS presents in multiple clinical situations as well, which may represent multiple variations in KSHV pathogenesis. Before the introduction of combination antiretroviral therapy (cART), AIDS KS was negatively correlated with CD4 counts. The majority of AIDS KS continues to present in persons with low CD4 counts and indicates cART failure. However, 1/3 of KS now presents in HIV+ individuals on successful long-term cART, despite undetectable HIV viral load and despite near-normal CD4 counts [20] . Lastly, KS immune reconstitution syndrome has been recognized as a complication of cART initiation, where rapid immune restoration leads to the development of KS lesions [21] . On the basis of limited data, KS that develops in HIV-suppressed individuals exhibits a more restricted viral gene expression profile [13] .
The molecular drivers of KS are unclear. On the one hand, we do not know of any specific cellular mutation that is associated with KS. On the other hand, we do know the transcriptional profiles of KS and endothelial-based model systems for KS. Profiling studies, together with the analyses of individual proteins, confirm that the tissue of origin for KS is an endothelial cell. More detailed lineage assignments are difficult to make. There exists evidence of trans-or de-differentiation of endothelial cells in response to KSHV infection and/or transformation to KS tumor cells as well as evidence for the expression of markers not exclusively associated with endothelial cells [15 ,22] . The most exciting recent discovery is that of the ephrin receptor kinase A2 (ephA2) as a receptor for KSHV [23 ,24 ] .
KSHV-Inflammatory Cytokine Syndrome (KICS)
Primary KSHV infection does not usually result in a notable clinical phenotype. Reports of KSHV-associated mononucleosis or rash are few and far between. KSHV infection of immune competent primates mirrors the paucity of phenotypes seen in human infection. Recently, however, a new clinical entity has been proposed that describes a severe systemic infection and/or reactivation with KSHV: KSHV-Inflammatory Cytokine Syndrome (KICS) [21, 25, 26] . It is associated with high-level viremia, KS, and a severe cytokine storm in the absence of multicentric Castleman's disease (MCD) in HIV+ patients. Whether this rare disease is the result of a viral variant or a rare genetic predisposition, analogous to X-linked predispositions to chronic viral infections, is presently unresolved. The most likely driver of the clinical phenotype seems to be the production of KSHV vIL6 and human IL6 induction by KSHV.
KSHV in B cells
KSHV establishes latency in B cells. Latency in B cells can be asymptomatic and is most likely restricted to a subset of B cells, which unlike EBV+ CD27+ memory B cells do not circulate in large numbers in peripheral blood [27] . KSHV seems to have a predilection for infecting and establishing long-term latency in only lambda expressing B cells [27, 28] . KSHV infection drives primary B cells to proliferation [27] . Infection with the related MHV68 virus also induced B cell hyperplasia and resulted in fully transformed B cells [29] . Individual KSHV latent genes induce B cell proliferative phenotypes in transgenic mice. LANA transgenic mice developed splenic follicular hyperplasia, which is dependent on B cell receptor (BCR) signaling [30] . vFLIP transgenic mice develop either lymphoma or histiocydic sarcoma [31] . KSHV vIL6 transgenic mice develop hyperplasia reminiscent of MCD [32] . The viral cyclin (vCyc) gene integrates different properties of the host cyclins to foster a pro-growth and pro-virus environment [33] . Individual KSHV miRNAs also have transforming properties in in vivo B cell models, particularly the KSHV mir-155 ortholog [34] . Viral genes from the related MHV68 virus display similar phenotypes (reviewed in [35] ). B cell specific expression of multiple viral latent KSHV proteins as well as the viral miRNAs leads to sustained hyperplasia, lymphoma, and hyper-responsiveness to antigen stimulation [36] .
A putative model of KSHV B cell pathogenesis would start with the primary infection event, which drives the infected cell into an activated state. This holds true even for non-permissively infected cells. In non-permissive cell subtypes, such as IgM+ kappa B cells, or T cells [37] , the virus is rapidly lost or the cell dies. In cells that are competent for the establishment of latency, the virus persists and now confers a survival advantage to the infected cell. The molecular nature of this advantage, and the exact complement of viral genes that confer this advantage are not well defined. It may very well be that genes, other than those consistently detected in KSHV tumor cells may contribute to this phenotype. This model would be analogous perhaps to the establishment of EBV latency, which starts out with expressing a more extensive set of genes and then contracts to latency type I or even type 0.
MCD and PEL
Once established in B cells, KSHV can lead to multiple disease manifestations, as additional mutations accumulate in the host genome over time. These B lymphoproliferative diseases include primary effusion lymphoma (PEL) and the plasmablastic variant of MCD (reviewed in [38] ) and in rare instances, diffuse large B cell lymphoma not presenting as effusions. There is also the titillating observation that KSHV increases the risk of marginal zone lymphoma (MZ) [39] , and the ever present, but controversial speculation that KSHV can be found in, contribute to, or survive better in multiple myeloma cells.
MCD is considered a lymphoproliferative disorder rather than a frank lymphoma. The KSHV infected plasmablasts invariably express IgM lambda. KSHV latent genes, as well as the viral IL6 homolog are expressed in a large fraction of MCD cells (reviewed in [3, 38] ). Unlike PEL, MCD cells do not express the CD138/syndecan-1 marker, and also do not show hyper mutation of the IgG locus, which would argue that these cells did not participate in the canonical germinal center reaction. The viral IL6 protein, as well as elevated human IL6, seems to drive much of the clinical symptomology of MCD, which provides a novel rational target for intervention, perhaps using IL6 neutralizing antibodies [40] .
PEL is a diffuse large B cell lymphoma of post germinal center origin [3, 38] . All PEL cells express CD138/syndecan-1, the KSHV LANA protein, the viral miRNAs and other latent genes (vCYC, vFLIP, kaposin, vIRF3/ LANA-2) [41 ,42 ] . A more detailed review about KSHV gene expression is provided elsewhere in this issue. PEL cells contain many KSHV episomes, ranging from 40 to 80 copies per cell. 50% of PEL are co-infected with EBV and the EBV positive PEL exhibit a different pattern of gene expression compared to EBV-negative PEL. At present there is no evidence that EBV-positive 240 Viral pathogenesis PEL have a different clinical outcome, respond differently to treatment, or behave differently in experimental models of tumor growth. In addition to KSHV, PEL have sustained multiple genomic alterations as ascertained by CGH [43, 61] , though the total number of cases has been too small to identify a single host cell driver mutation with a high degree of statistical significance.
The relatively consistent growth of PEL cell lines in culture and the fact that many PEL can be induced to release infectious KSHV have made them the workhorse for molecular studies in KSHV pathogenesis. There is no evidence that the virus trapped in PEL cells is defective (though the small number of cell lines which can be propagated in culture means that our knowledge about PEL biology may be heavily biased). PEL represent the extreme end of KSHV pathogenesis: a fully transformed cell, which maintains the KSHV genome in high copy numbers, has acquired additional mutations, and which easily establishes tumors in immune deficient mice (regardless of site of injection). Many PEL cell lines were derived after, and thus selected to survive, multiple rounds of chemotherapy. Importantly, all PEL cell lines depend on the presence of KSHV and the continued expression of KSHV genes for survival (reviewed in [3, 6, 38] ).
Modulation of the innate immune response by KSHV
Similar to other herpesviruses, KSHV has to escape the host immune response during initial infection, during sustained latency, and during reactivation. The clinical experience is that first, KSHV successfully establishes latency and thus overcomes the initial host barriers to infection and second, that KS lesions spontaneously regress after immune reconstitution. MCD also wanes with immune reconstitution and MCD symptoms have a cyclical pattern. PEL never regresses but grows relentlessly in an immune compromised host. The survival time of PEL in the absence of cytotoxic (and thus immune suppressive) therapy is less than the typical time of immune reconstitution after cART initiation.
The host uses two levels of defense to counter microbial infection; the innate immune system (initial recognition of the incoming pathogen) and the adaptive immune system (systemic recognition and memory response to the pathogen). The innate immune response initiates the adaptive response, which may eventually lead to pathogen clearance. KSHV has evolved multiple molecular mechanisms to evade host immunity. These are described elsewhere in this volume. Here we focus on one aspect to the virus-host interaction, which is the interface of KSHV with the innate immune system. [45] ).
The nucleotide-binding oligomerization domain receptor (NLR) family of innate immune sensors has been implicated in many human diseases (reviewed in [46] ). NLRs sense PAMPs, danger associated molecular patterns (DAMPs), as well as environmental irritants. Some NLR family members regulate innate immunity through the formation of large molecular complexes called inflammasomes, which lead to the upregulation of IL-1b and IL-18. Other NLRs can inhibit NF-kB and type I IFN signaling, suggesting that this pathway has evolved mechanisms to regulate itself. Inflammasomes generally consist of oligomerization of a particular NLR, recruitment of procaspase-1 and apoptotic-associated speck-like protein (ASC). To date, several NLR family members have been shown to form inflammasomes including NLRP1, NLRP3, and NLRC4. KSHV Orf63 was shown to inhibit NLRP1-and NLRP-3 inflammasome activity and prevent the processing and activation of pro-IL-1b and pro-IL-18 to active IL-1b and IL-18 [47 ] .
There also exist non-NLR containing inflammasomes, and KSHV has been to shown to activate interferoninducible factor 16 (IFI16) to induce the inflammasome in KSHV-infected endothelial cells [48 ,49] . 
Conclusions
Our insights into KSHV have significantly advanced in the recent years. A new disease entity (KICS) has been identified as being associated with acute KSHV replication. Previously recognized KSHV diseases, such as KS, continue to lead the global cancer burden in people living with HIV/AIDS. Additionally, recent advances have also been made in our understanding of how KSHV modulates autophagy, host metabolism, differentiation and innate immune responses. New tools, such as new animal model systems are on the horizon, which will allow us to investigate the life cycle of KSHV and of viral pathogenesis before the development of disease phenotypes. At the same time, almost 20 years after the discovery of KSHV, simple cytotoxic chemotherapy regimens remain the only clinically validated treatments. Currently, there exists no vaccine against this virus and, with the exception perhaps of mTOR inhibitors [17,58,59 ,60] , no targeted agents have been added to clinical practice.
